CN112512531B - 用于膀胱癌的治疗的方法 - Google Patents

用于膀胱癌的治疗的方法 Download PDF

Info

Publication number
CN112512531B
CN112512531B CN201980050644.2A CN201980050644A CN112512531B CN 112512531 B CN112512531 B CN 112512531B CN 201980050644 A CN201980050644 A CN 201980050644A CN 112512531 B CN112512531 B CN 112512531B
Authority
CN
China
Prior art keywords
compound
sting
vol
mixture
bladder cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980050644.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN112512531A (zh
Inventor
金大式
方家范
远藤笃史
崔亨旭
郝鸣鸿
鲍幸峰
黄冠群
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN112512531A publication Critical patent/CN112512531A/zh
Application granted granted Critical
Publication of CN112512531B publication Critical patent/CN112512531B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201980050644.2A 2018-06-01 2019-05-31 用于膀胱癌的治疗的方法 Active CN112512531B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862679495P 2018-06-01 2018-06-01
US62/679,495 2018-06-01
US201962826347P 2019-03-29 2019-03-29
US62/826,347 2019-03-29
PCT/US2019/034933 WO2019232392A1 (en) 2018-06-01 2019-05-31 Methods for the treatment of bladder cancer

Publications (2)

Publication Number Publication Date
CN112512531A CN112512531A (zh) 2021-03-16
CN112512531B true CN112512531B (zh) 2024-04-09

Family

ID=67138025

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980050644.2A Active CN112512531B (zh) 2018-06-01 2019-05-31 用于膀胱癌的治疗的方法

Country Status (11)

Country Link
US (1) US12251394B2 (https=)
EP (1) EP3801561B1 (https=)
JP (1) JP7335277B2 (https=)
KR (1) KR20210015937A (https=)
CN (1) CN112512531B (https=)
AU (1) AU2019277679B2 (https=)
BR (1) BR112020024605A2 (https=)
CA (1) CA3101623A1 (https=)
MX (1) MX2020012964A (https=)
SG (1) SG11202011434SA (https=)
WO (1) WO2019232392A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
JP2024533394A (ja) 2021-09-09 2024-09-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｓｔｉｎｇアゴニストのバイオマーカー及びその使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016120305A1 (en) * 2015-01-29 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Cyclic dinucleotides useful for the treatment of inter alia cancer
WO2017027645A1 (en) * 2015-08-13 2017-02-16 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
WO2018152450A1 (en) * 2017-02-17 2018-08-23 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides compounds for the treatment of cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
WO2005089777A1 (en) 2004-03-15 2005-09-29 Karaolis David K R A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
US7592326B2 (en) 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
WO2009133560A1 (en) 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
CN102199183B (zh) 2010-03-26 2013-12-18 北京大学 环二鸟苷酸及其类似物和制备方法
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
WO2015074145A1 (en) 2013-11-22 2015-05-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
CR20160564A (es) 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos como moduladores de sting
EP3546473B1 (en) 2014-12-16 2025-12-10 Kayla Therapeutics Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
US20180344758A1 (en) 2014-12-17 2018-12-06 Lipogen Llc Method of Treating Cancer with cGAMP or cGAsMP
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
JP2018534295A (ja) 2015-10-28 2018-11-22 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法
CN107849084B (zh) 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
US10723756B2 (en) 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
JOP20170188A1 (ar) 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
US20190336615A1 (en) 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
WO2018198084A1 (en) 2017-04-27 2018-11-01 Lupin Limited Cyclic di-nucleotide compounds with tricyclic nucleobases
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
AR113224A1 (es) * 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
MX2020002303A (es) 2017-08-30 2020-09-10 Beijing Xuanyi Pharmasciences Co Ltd Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon.
WO2019046511A1 (en) 2017-08-31 2019-03-07 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE
US10947263B2 (en) 2017-08-31 2021-03-16 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
KR102812783B1 (ko) 2017-08-31 2025-05-26 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
JP7208225B2 (ja) 2017-08-31 2023-01-18 ブリストル－マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016120305A1 (en) * 2015-01-29 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Cyclic dinucleotides useful for the treatment of inter alia cancer
WO2017027645A1 (en) * 2015-08-13 2017-02-16 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
WO2018152450A1 (en) * 2017-02-17 2018-08-23 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides compounds for the treatment of cancer

Also Published As

Publication number Publication date
WO2019232392A1 (en) 2019-12-05
JP7335277B2 (ja) 2023-08-29
CN112512531A (zh) 2021-03-16
US12251394B2 (en) 2025-03-18
CA3101623A1 (en) 2019-12-05
US20210205348A1 (en) 2021-07-08
MX2020012964A (es) 2021-02-16
AU2019277679B2 (en) 2024-11-28
SG11202011434SA (en) 2020-12-30
EP3801561A1 (en) 2021-04-14
JP2021525758A (ja) 2021-09-27
BR112020024605A2 (pt) 2021-04-06
KR20210015937A (ko) 2021-02-10
EP3801561B1 (en) 2025-03-19
AU2019277679A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
TWI766948B (zh) 用於治療癌症之化合物
JP7506079B2 (ja) がんの治療に用いるためのヘテロ環ｎｌｒｐ３モジュレーター
CN112512531B (zh) 用于膀胱癌的治疗的方法
CN113301963A (zh) 用于治疗癌症的作为nlrp3调节剂的取代的喹唑啉类
EP3125901B1 (en) Derivatives of cephalosporin for treating cancer
EP3860988A1 (en) Crystalline forms of niraparib freebase
RU2795220C2 (ru) Способы лечения рака мочевого пузыря
KR20140107576A (ko) Braf 저해제 및/또는 mek 저해제와 magea3 면역치료제를 이용한 암 치료 방법
CN112041325B (zh) 化合物的盐及其晶体
JP7573622B2 (ja) Ｎｌｒｐ３モジュレーター
US20200347136A1 (en) Constrained cyclic peptides as inhibitors of the cd2:cd58 protein-protein interaction for treatment of diseases and autoimmune disorders
RU2790175C2 (ru) Циклические ди-нуклеотидные соединения для лечения рака
WO2024140754A1 (zh) 一种萘酰胺类化合物、其制备方法及其应用
BR112019017084B1 (pt) Compostos dinucleotídeos cíclicos, composições farmacêuticas que compreendem os mesmos e uso dos ditos compostos para o tratamento de câncer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant